An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic
J. Clin. Invest. 117:12 doi:10.1172/JCI32373
[Go to this article.]

Problems with a PDF?

PDF - Download (1.41 MB)